切换至 "中华医学电子期刊资源库"

中华肾病研究电子杂志 ›› 2015, Vol. 04 ›› Issue (02) : 78 -81. doi: 10.3877/cma.j.issn.2095-3216.2015.02.005

所属专题: 文献

专家论坛

骨髓瘤肾病的中西医结合治疗
郭志勇1,(), 董睿1   
  1. 1. 200433 上海第二军医大学附属长海医院肾内科
  • 出版日期:2015-04-28
  • 通信作者: 郭志勇

Treatment of myeloma nephropathy with integrated traditional Chinese and western medicine

Zhiyong Guo1,(), Rui Dong1   

  1. 1. Department of Nephrology, Changhai Hospital Affiliated to Second Military Medical University, Shanghai 200433, China
  • Published:2015-04-28
  • Corresponding author: Zhiyong Guo
  • About author:
    Corresponding author: Guo Zhiyong, Email:
引用本文:

郭志勇, 董睿. 骨髓瘤肾病的中西医结合治疗[J/OL]. 中华肾病研究电子杂志, 2015, 04(02): 78-81.

Zhiyong Guo, Rui Dong. Treatment of myeloma nephropathy with integrated traditional Chinese and western medicine[J/OL]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2015, 04(02): 78-81.

多发性骨髓瘤(MM)是浆细胞系异常增生的恶性疾病,常伴有肾脏损害、高钙血症、骨病、高粘滞血症、贫血、感染、血栓等;伴有肾脏损害的患者约占50%,其肾脏损害多表现为管型肾病,其中约9%的患者需要透析治疗。骨髓瘤肾病的西医治疗主要包括:水化、避免肾损害的药物使用,血浆置换、血液透析以及原发病的化疗及干细胞移植。中医治疗主要是在西医治疗的基础上进行的中医辨证论治,主要效果在于增强机体免疫力、提高化疗敏感性、促进正常造血功能恢复、减轻主观症状、减少西医治疗的并发症等。

Multiple myeloma (MM) is a malignant disease with abnormal proliferation of plasma cells, often accompanied with renal impairment (RI), hypercalcemia, bone disease, hyperviscositemia, anemia, infection, thrombosis, etc. Patients with RI account for about 50% of MM. Most RI manifested as cast nephropathy, of which about 9% need dialysis treatment. The western medicine treatment for RI of MM mainly includes adequate hydration, avoidance of using agents that contribute to renal damage, plasma exchange, hemodialysis, chemotherapy for primary disease, and stem cell transplantation; while the traditional Chinese medicine treatment for RI of MM is based on the western medicine treatment, providing treatment on the base of syndrome differentiation, the main effects of which were comprised of enhancing immunity, improving chemotherapy sensitivity, promoting recovery of normal hematopoietic function, reducing subjective symptoms, and decreasing complications of western medicine treatment.

[1]
Knudsen LM, Hippe E, Hjorth M, et al. Renal function in newly diagnosed multiple myeloma - a demographic study of 1353 patients [J]. Eur J Hematol, 1994, 53(4): 207-212.
[2]
Boccadoro M, Palumbo A, Argentino C, et al. Conventional induction treatments do not influence overall survival in multiple myeloma [J]. Br J Haematol, 1997, 96(2): 333-337.
[3]
Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma [J]. N Engl J Med, 1996, 335(2):91-97.
[4]
Anderson KC, Alsina M, Bensinger W, et al. NCCN clinical practice guidelines in oncology: multiple myeloma [J]. J Natl Compr Canc Netw, 2009, 7(9): 908-942.
[5]
郝敬全,刘璇,雷秋红,等. 中医药治疗多发性骨髓瘤概况[J]. 湖南中医杂志,2011,27(5):137-138.
[6]
Sanders PW, Herrera GA, Galla JH. Human Bence Jones protein toxicity in rat proximal tubule epithelium in vivo [J]. Kidney Int, 1987, 32(6): 851-861.
[7]
Solomon A, Weiss DT, Kattine AA. Nephrotoxic potential of Bence Jones proteins [J]. N Engl J Med, 1991, 324(26): 1845-1851.
[8]
Leboulleux M, Lelongt B, Mougenot B, et al. Protease resistance and binding of Ig light chains in myeloma associated tubulopathies [J]. Kidney Int, 1995, 48(1): 72-79.
[9]
Myatt EA, Westholm FA, Weiss DT, et al. Pathogenic potential of human monoclonal immunoglobulin light chains: relationship of in vitro aggregation to in vivo organ deposition [J]. Proc Natl Acad Sci USA, 1994, 91(8): 3034-3038.
[10]
陈楠.多发性骨髓瘤肾脏损害诊断和治疗[J].内科理论与实践,2007,12(6):373-375.
[11]
Magee C, Vella JP, Tormey WP, et al. Multiple myeloma and renal failure: one center′s experience [J]. Ren Fail, 1998, 20(4): 597-606.
[12]
Moist L, Nesrallah G, Kortas C, et al. Plasma exchange in rapidly progressive renal failure due to multiple myeloma [J]. Am J Nephrol, 1999, 19(1): 45-50.
[13]
戴媺,陈志雄.补肾法在血液病中的临床应用[J].医药论坛杂志,2007,28(10):121-122.
[14]
刘琨,李达,张宏业.87例多发性骨髓瘤的中医证型分析[J].新中医,2007,39(8):57-58.
[15]
蒋楠,甘欣锦.中医辨治多发性骨髓瘤的体会[J].甘肃中医,2005,18(1):7-8.
[16]
杨月艳.多发性骨髓瘤的中医辨治特点[J].山西中医,2008,24(1):59-60.
[17]
潘铭.中西医结合治疗多发性骨髓瘤21例疗效分析[J].中医药学报,2008,36(1):72-73.
[18]
苏凤哲.中医药治疗多发性骨髓瘤临床探讨[J].世界中西医结合杂志,2007,2(9):551.
[1] 陈慧, 姚静, 张宁, 刘磊, 马秀玲, 王小贤, 方爱娟, 管静静. 超声心动图在多发性骨髓瘤心脏淀粉样变中的诊断价值[J/OL]. 中华医学超声杂志(电子版), 2024, 21(10): 943-949.
[2] 史学兵, 谢迎东, 谢霓, 徐超丽, 杨斌, 孙帼. 声辐射力弹性成像对不可切除肝细胞癌门静脉癌栓患者放射治疗效果的评价[J/OL]. 中华医学超声杂志(电子版), 2024, 21(08): 778-784.
[3] 曹琮沅, 黄烁金, 何倩婷, 王安训. 平阳霉素复合剂治疗口腔颌面部脉管畸形的有效性和安全性[J/OL]. 中华口腔医学研究杂志(电子版), 2024, 18(06): 368-374.
[4] 严华悦, 刘子祥, 周少波. 磷酸烯醇式丙酮酸羧激酶-1在恶性肿瘤中的研究进展[J/OL]. 中华普通外科学文献(电子版), 2024, 18(06): 452-456.
[5] 高俊颖, 张海洲, 区泓乐, 孙强. FOLFOX-HAIC 为基础的肝细胞癌辅助转化治疗的应用进展[J/OL]. 中华普通外科学文献(电子版), 2024, 18(06): 457-463.
[6] 李华志, 曹广, 刘殿刚, 张雅静. 不同入路下行肝切除术治疗原发性肝细胞癌的临床对比[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 52-55.
[7] 陈浩, 王萌. 胃印戒细胞癌的临床病理特征及治疗选择的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 108-111.
[8] 刘柏隆, 周祥福. 压力性尿失禁阶梯治疗的项目介绍[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(01): 125-125.
[9] 刘柏隆. 女性压力性尿失禁阶梯治疗之手术治疗方案选择[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(01): 126-126.
[10] 中华医学会器官移植学分会. 肝移植术后缺血性胆道病变诊断与治疗中国实践指南[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 739-748.
[11] 陈伟杰, 何小东. 胆囊癌免疫靶向治疗进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 763-768.
[12] 王秋生. 胆道良性疾病诊疗策略[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 779-782.
[13] 陈杰, 武明胜, 李一金, 李虎, 向源楚, 荣新奇, 彭健. 低位直肠癌冷冻治疗临床初步分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 494-498.
[14] 崔军威, 蔡华丽, 胡艺冰, 胡慧. 亚甲蓝联合金属定位夹及定位钩针标记在乳腺癌辅助化疗后评估腋窝转移淋巴结的临床应用价值探究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 625-632.
[15] 王誉英, 刘世伟, 王睿, 曾娅玲, 涂禧慧, 张蒲蓉. 老年乳腺癌新辅助治疗病理完全缓解的预测因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 641-646.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?